2009•Critical Care MedicineOpen access

Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis*

Amisha V. Barochia, Xizhong Cui, Charles Natanson, Peter Q. Eichacker

Open full text 12 citations

Abstract

Barochia, Amisha V. MBBS; Cui, Xizhong MD, PhD; Natanson, Charles MD; Eichacker, Peter Q. MD Author Information

About this research paper

What this paper is about

Barochia, Amisha V. MBBS; Cui, Xizhong MD, PhD; Natanson, Charles MD; Eichacker, Peter Q. MD Author Information

Why it matters

OpenAlex reports 12 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Barochia, Amisha V. MBBS; Cui, Xizhong MD, PhD; Natanson, Charles MD; Eichacker, Peter Q. MD Author Information

Key concepts: Medicine, Sepsis, Clinical trial, Pharmacology, Intensive care medicine, Immunology, Internal medicine

Back to paper search Browse research topics Original source

Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis* — Research Paper | ScholarLens

Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis*

About this research paper

What this paper is about

Why it matters

Key contribution

Method / approach

Main findings

Limitations

Applications

Available abstract

Related papers